Compare Amphastar Pharmaceuticals Inc (AMPH) vs Datadog Inc (DDOG) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Datadog (DDOG) trades at $257.54, down 4.25% on the day, with strong technical momentum indicators showing bullish moving averages but overbought RSI readings. The company maintains impressive revenue growth, reaching $3.43B in 2025, with consistent earnings beats in recent quarters. Recent acquisition of Adaptive ML positions DDOG for AI-driven growth, though valuation metrics remain elevated with P/E of 660 and P/S of 25.5.

Outlook remains positive with 83% analyst buy ratings and $246 consensus target, though current price exceeds target. Key risks include high valuation multiples, moderating growth guidance, and competitive pressures in cloud observability. The stock's 88.7% YTD surge suggests much optimism is priced in, requiring continued execution to justify premium valuation.